Paidoterin descongestivo jarabe инструкция

Dating > Paidoterin descongestivo jarabe инструкция

Download links: → Paidoterin descongestivo jarabe инструкция → Paidoterin descongestivo jarabe инструкция

Так Грейс позвонила Кате, чтобы уточнить, оденет ли она ту пижаму, ей хотелось, чтобы они были одеты в одинаковые пижамы. Prospecto: información para el usuario. Paidoterin descongestivo инструкция Поколению года: Форум Кофейня Ответить Цитировать Пожаловаться 7470 Мне нравится 0.

Los antidepresivos tricíclicos podrían potenciar los efectos vasopresores de las aminas simpaticomiméticas, dando lugar a crisis hipertensivas. Iniston antitusivo y descongestivo jarabe 120 ml. Если риски от применения выше, чем от самой болезни, а эффект от применения равен эффекту плацебо, препарат применятья не должен. NO está compuesto por alguna sustancia psicotrópica. Las convulsiones se tratarán con diazepam y la hipotensión severa con nitroprusiato o fentolamina. Если что ты проси конкретнее, а не просто от насморка, говори, что тебе надо, какой эффект. Так Грейс позвонила Кате, чтобы уточнить, оденет ли она ту пижаму, ей хотелось, чтобы они были одеты в одинаковые пижамы. Fuente del texto y de las imágenes: Digitalizado a partir del prospecto en papel. If you do not specify a display name, your given name will be used. Contraindications Hypersensitivity to any of the components of the medicament.

Alcohol: el uso simultáneo puede potenciar los efectos depresores sobre el SNC del alcohol o de los antihistamínicos. Лично мне эти форумы очень помогают учиться, вести свою private medical practice и готовиться к USMLE. NO está compuesto por alguna sustancia psicotrópica.

Paidoterin descongestivo jarabe инструкция - Pregnancy and lactation It has not been established the innocuousness of PAIDOTERIN DECONGESTANT in pregnancy. Should the anticholinergic effects be intractable it will be administered physostigmine.

Qualitative and quantitative composition Per 5 ml of syrup: phenylephrine chlorhydrate D. Therapeutic indications It is indicated for the relief of the symptoms of the congestion of the mucosa de of the upper airways, which accompanies perennial or seasonal allergic rhinitis. Children aged 2 to 6: 1 spoonful every 6 to 8 hours. Children aged 6 to 12: 2-3 spoonfuls every 6 or 8 hours. Adults: 3-4 spoonfuls every 6 or 8 hours. To be administered preferably after meals. One spoonful is equivalent to 5 ml. As an alternative option, the dosage can be carried out using the dispenser cup with marks at 2,5, 5, 10, 15 and 20 ml included in the presentation. It should not be exceeded, at most, twice the indicated doses for each of the intakes. Contraindications Hypersensitivity to any of the components of the medicament. The speciality PAIDOTERIN DECONGESTANT should be administered very cautiously in patients with hypertension, serious cardiovascular diseases, glaucoma, prostatic hypertrophy, obstruction of the vesical neck and urinary retention. Warnings and special precautions of use Patients sensitive to an antihistaminic can be sensitive to other antihistaminics. Sportspeople should be aware that this medicament contains a component that may establish a positive analytic result in a doping control. It is not recommended the use of this medicament in children younger than 1. Newborns and premature babies show a greater sensitivity to the anticholinergic side effects. In older children being treated with antihistaminics a paradoxical reaction characterized by hyper-excitability can occur. Use in old people: in these patients anticholinergic and SNC stimulant effects are likely to occur, there is danger of precipitating a non-diagnosed glaucoma. Interaction with other medicaments and other ways of interaction Medicaments that cause depression on the SNC: the simultaneous use can reinforce the depressant effects on the SNC of these medicaments or of the antihistaminics. Tricyclic antidepressants: The simultaneous use with antihistaminics can reinforce the depressant effects on the SNC of tricyclic antidepressants or of the antihistaminics content in these associations, as well as the anticholinergic effects. They can also reinforce the cardiovascular effects of phenylephrine. Maprotiline: the simultaneous use can reinforce the depressant effects either on the SNC of the maprotiline, or of the antihistaminics, as well as the anticholinergic effects of the antihistaminics or of these medicaments. The cardiovascular effects of the phenylephrine can also be reinforced. Inhibitors of monoamine-oxidase MAO , including furazolidone, pargiline and procarbazine: the simultaneous use with antihistaminics can prolong and intensify the antimuscarinic and depressant effects of the SNC of antihistaminics. Anticholinergics or other medicaments with anticholinergic action: The anticholinergic effects can be reinforced. Alcohol: the simultaneous use can reinforce the depressant effects on the SNC of alcohol or antihistaminics. Sympathomimetic amines: the simultaneous use with sympathomimetic amines can prolong and intensify their cardiac and vasopressor stimulant effects. Adrenergic alpha-blockers: administered prior to phenylephrine they can block the presser response to phenylephrine and produce serious hypotension. It can also reduce the presser effect and shorten the duration of the action of phenylephrine. Inhaled halogenated hydrocarbons anaesthetics: when they are used simultaneously with phenylephrine they can increase the risk of serious ventricular arrhythmias. Local anaesthetics: phenylephrine should not be used together with a local anaesthetic to anaesthetize areas irrigated by terminal arteries due to the risk of ischemia. Adrenergic Beta Blockers: The therapeutic effects of these drugs can be inhibited when they are used together with phenylephrine; in the same way, adrenergic beta-blockers can give rise to alpha-adrenergic activity without opposition, with risk of hypertension and excessive bradycardia. Digitalic glucosides: the simultaneous use with phenylephrine can increase the risk of cardiac arrhythmias. Rye ergot and methysergide Alkaloids: the simultaneous use of dihydroergotamine, ergometrine, methylergometrine or methysergide with phenylephrine can cause an increase in vasoconstriction. Phenylephrine also interacts with ergoloideal mesilates or ergotamines and a simultaneous use is not recommended. Doxapram: the simultaneous use with phenylephrine can increase the presser effects of any of both products. Methyldopa or trimethaphan: the simultaneous use with phenylephrine can reinforce the presser response to phenylephrine. Pregnancy and lactation It has not been established the innocuousness of PAIDOTERIN DECONGESTANT in pregnancy. It is not recommended its use in nursing women due to the fact that adverse effects can occur in the child, such as unusual excitement or irritability, since small quantities of antihistaminics are excreted in milk. Effects on the ability to drive vehicles and operate machinery Since this medicament can cause somnolence, it can affect the ability to drive vehicles and operate machinery, since it can be dangerous. Adverse reactions Exceptionally somnolence may occur. Rarely blood dyscrasia may appear, increase of the sensitivity of skin to sun, increase in sweating and appetite loss. Also very rarely a paradoxical reaction nightmares, excitement, nervousness, etc. Overdosage In the event of acute intoxication from overdosage, the treatment consists of the administration of an emetic or a gastric lavage with sodium bicarbonate solution at 5%, activated carbon and catharsis. Should ventricular tachycardia appear lidocaine should be administered and propranolol if there is no response. In the event of seizures, diazepam. In the event of severe hypertension, nitroprusside or phentolamine. Should the anticholinergic effects be intractable it will be administered physostigmine. Haemodialysis and haemoperfussion are of limited utility. In the event of heart failure vasopressor support will be provided and if it fails, intra-aortic balloon. In patients with symptoms urine controls and controls about electrolytes in blood will be carried out. Pharmacological properties Pharmacodynamic properties: Therapeutic group: R06. The speciality PAIDOTERIN DECONGESTANT is an association of three de active ingredients: diphenhydramine chlorhydrate derived from ethanolamine , chlorpheniramine maleate derived from propylamine and phenylephrine chlorhydrate. Diphenhydramine chlorhydrate and chlorphenyramine maleate are two antihistaminics that act competing with the histamine released from the mast cells in the mucous membranes by the H1 receptors located in the target organs. They avoid, but they do not revert, the histamine-mediated responses. The antimuscarinical actions of the antihistaminics provide a drying effect on the nasal mucosa. Phenylephrine is a sympathomimetic amine that acts on the alpha-adrenergic receptors of the respiratory tract mucosa to produce vasoconstriction that reduces temporally the swelling associated to the inflammation of the mucous membranes that cover the nasal tract, acting as a decongestant. Pharmacokinetic properties: Phenylephrine chlorhydrate is absorbed irregularly in the gastrointestinal tract and it undergoes an extensive first-pass metabolism that takes place in the intestine and in the liver through the monoaminooxidase. Diphenhydramine chlorhydrate is easily absorbed after its oral administration, appearing the effects in 15-60 minutes. The maximum concentration of the drug is reached in about 2 hours. Its biotransformation is hepatic mainly and renal in a small percentage. The elimination is renal. Chlorpheniramine maleate is absorbed slowly from the gastrointestinal tract and the maximum plasmatic concentrations appear 2 to 6 hours after the oral administration. Chlorpheniramine seems to suffer a considerable first-pass metabolism. The excretion is mainly through urine. The minimum lethal dose estimated for children of up to 2 years is 100 mg by the intranasal route and it is 1 for adults g. The minimum lethal dose is 3 g. Incompatibilities MAO Inhibitors monoaminooxidase. Shelf-life The shelf-life of the product packaged to be commercialized: 5 years. Special precautions of storage It does not require special precautions. The bottle should be protected from light and from excessively low temperatures. Nature and content of the container Polyethylene bottles and polypropylene cap. A polypropylene dispenser cup also included with marks at 2,5 ,5, 10, 15 and 20 ml. The volume of syrup per bottle is 100 ml. Refundable by the National Health System.